EP1556515B1 - Methods for assessing efficacy of chemotherapeutic agents - Google Patents
Methods for assessing efficacy of chemotherapeutic agents Download PDFInfo
- Publication number
- EP1556515B1 EP1556515B1 EP03779093A EP03779093A EP1556515B1 EP 1556515 B1 EP1556515 B1 EP 1556515B1 EP 03779093 A EP03779093 A EP 03779093A EP 03779093 A EP03779093 A EP 03779093A EP 1556515 B1 EP1556515 B1 EP 1556515B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- patient
- drug
- explant
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 71
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 49
- 229940127089 cytotoxic agent Drugs 0.000 title abstract description 45
- 230000000973 chemotherapeutic effect Effects 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 113
- 238000003556 assay Methods 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 23
- 239000002356 single layer Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 20
- 238000012247 phenotypical assay Methods 0.000 claims description 18
- 210000004881 tumor cell Anatomy 0.000 claims description 15
- 230000012010 growth Effects 0.000 claims description 14
- 238000004458 analytical method Methods 0.000 claims description 13
- 238000004113 cell culture Methods 0.000 claims description 13
- 210000004748 cultured cell Anatomy 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 206010059866 Drug resistance Diseases 0.000 claims description 9
- 210000002536 stromal cell Anatomy 0.000 claims description 9
- 230000009087 cell motility Effects 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 102000001301 EGF receptor Human genes 0.000 claims description 4
- 108060006698 EGF receptor Proteins 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 230000001594 aberrant effect Effects 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 230000030833 cell death Effects 0.000 claims description 3
- 238000013467 fragmentation Methods 0.000 claims description 3
- 238000006062 fragmentation reaction Methods 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 210000001082 somatic cell Anatomy 0.000 claims description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 2
- 102000006311 Cyclin D1 Human genes 0.000 claims description 2
- 108010058546 Cyclin D1 Proteins 0.000 claims description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 206010070863 Toxicity to various agents Diseases 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 230000021164 cell adhesion Effects 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000002771 cell marker Substances 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 1
- 230000036267 drug metabolism Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000009897 systematic effect Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 abstract description 26
- 238000011282 treatment Methods 0.000 abstract description 14
- 238000001727 in vivo Methods 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000012602 chemosensitivity assay Methods 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 28
- 239000000523 sample Substances 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 14
- 238000002493 microarray Methods 0.000 description 14
- 238000001574 biopsy Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 229940124598 therapeutic candidate Drugs 0.000 description 10
- 229960004562 carboplatin Drugs 0.000 description 9
- 229930012538 Paclitaxel Natural products 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 229960001592 paclitaxel Drugs 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 206010071602 Genetic polymorphism Diseases 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 229940044683 chemotherapy drug Drugs 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 238000010835 comparative analysis Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010048723 Multiple-drug resistance Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108020005093 RNA Precursors Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000002783 cell motility assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000034724 negative regulation of cellular component movement Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000010865 video microscopy Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Definitions
- the invention relates to methods for assessing efficacy of chemotherapeutic agents.
- Cancer chemotherapy involves the use of cytotoxic drugs to destroy unwanted cells in patients. Treatment may consist of using one or more cytotoxic drugs, depending on the nature of the disease being treated. However, drug toxicity and drug resistance are significant barriers effective chemotherapy.
- chemotherapeutic agents Toxicity from chemotherapeutic agents produces side effects ranging from mild trauma to death. Moreover, repeated exposure to chemotherapeutic drugs is itself often fatal. As chemotherapeutic drugs are carried in the blood, they are taken up by proliferating cells, including normal cells. Tissues with high growth rates such as bone marrow and epithelial tissues, including the gastrointestinal tract, are normally most susceptible to toxic side effects. Some drugs have additional toxic effects on other tissues, such as the urinary tract, myocardium, or pancreas. Chemotherapeutic agents may cause direct injury to the heart, either acutely, in the form of myocardial tissue injury or dysrhythmias, or in a delayed or chronic fashion associated with congestive heart failure.
- Target cells such as malignant or diseased cells, may be intrinsically resistant to chemotherapeutic drugs or they may acquire resistance as a result of exposure.
- a target cell may be genetically predisposed to resistance to particular chemotherapeutics.
- the cell may not have receptors or activating enzymes for the drug or may not be reliant on the biochemical process with which the drug interferes.
- Acquired resistance also may develop after cells have been exposed to a drug or to similar classes of drugs.
- One example of acquired drug resistance is the multiple drug resistance phenotype.
- Multiple drug resistance is a phenomenon of cross-resistance of cells to a variety of chemotherapeutic agents which are not structurally or functionally related. This phenomenon is typically mediated by p-glycoprotein, a cell membrane pump that is present normally on the surface of some epithelial cells. The protein actively removes drug from the cell, making it resistant to drugs that are substrates for the cell membrane pump.
- WO9802038 discloses a method for assesing the chemotherapeutic effect for a patient by allowing a multicellular explant to form a monolayer, and conducting a phenotypic assay by treating cells with compounds, but the explant is not removed from the culture.
- a critical issue in cancer chemotherapy is the ability to select drugs that not only affect cancer cell phenotype in cell culture assays, but are also not subject to resistance.
- the present invention addresses that issue.
- the invention provides methods for accurately predicting efficacy of chemotherapeutic agents.
- Methods of the invention increase the positive predictive value of chemosensitivity assays by assessing both the ability of a chemotherapeutic to affect tumor cells phenotype and the genetic propensity of the patient for resistance to the chemotherapeutic.
- Results obtained using methods of the invention provide insight into the in vivo effectiveness of a therapeutic, and lead to more effective, individualized, chemotherapeutic choices.
- a phenotype assay screens a therapeutic candidate for the ability to affect the phenotype of tumor cells in culture.
- a therapeutic candidate that produces the desired phenotypic effect e.g., cell death, decreased motility, changes in cellular adhesion, angiogenesis, or gene expression, among others
- a therapeutic candidate that has a desired phenotypic effect on patient tumor cells and that does not appear to be subject to genetic-based resistance is selected for use.
- use of the invention increases the likelihood that a therapeutic candidate, chosen on the basis of its ability to affect cellular phenotype, will be effective when administered to patients.
- the invention provides methods for assessing efficacy of chemotherapeutic agents comprising exposing cells to a chemotherapeutic agent, conducting an assay to determine whether the chemotherapeutic agent affects tumor cell phenotype, and identifying genetic characteristics of cells of the patient (which may or may not be tumor cells) that indicate a propensity for resistance to the chemotherapeutic agent.
- a phenotypic assay for use in the invention comprises obtaining a tumor explant from a patient, culturing portions of he explant, allowing a multicellular tumor tissue explant to form a cell culture monolayer, removing the explant from the culture prior to the emergence of a substantial number of stromal cells from the explant and growing the monolayer to thereby prevent substantial growth of stromal cells, exposing the monolayer to a drug candidate, and assessing the ability of the drug candidate to alter tumor cell phenotype.
- a preferred phenotypic assay is disclosed in U.S. Patent No. 5,728,541 , and in co-owned, co-pending U.S. Application Serial No. 10/208,480 .
- Genotype analysis is accomplished by any known method.
- a preferred method comprises comparing the genotype, or portion thereof, of cells obtained from the patient with genotypes known to be associated with drug resistance generally, or specifically with respect to a therapeutic candidate being evaluated. For example, the existence in patient cells of a polymorphic variant that is known or suspected to confer resistance to a therapeutic candidate would screen that candidate out as a potential therapeutic against those cells.
- Genetic characteristics of patient cells are determined by methods known in the art (e.g., sequencing, polymorphisms) as set forth below.
- the impact of a patient's genotype upon drug resistance may be determined by reference to genetic databases or libraries that catalog known mutations or polymorphisms related to resistance.
- the present invention also provides methods for selecting a chemotherapeutic agent for treating a patient based on results obtained from the phenotypic and genotypic assays.
- the present invention allows for the assessment of whether a chemotherapeutic agent will be effective in treating a cancer when administered to a patient.
- chemotherapeutic agents or combinations of chemotherapeutic agents are selected for treatment where an effect on cellular phenotype is observed and characteristics of genetic-based resistance are not observed.
- Methods of the invention are useful in drug or chemotherapeutic agent screening to provide information indicative of the in vivo reactivity of the cells, and thus the specific efficacy as to a particular patient. Methods of the invention are also useful to screen new drug candidates for therapeutic efficacy and to provide a basis for categorizing drugs with respect to the tumor types against which they will work best.
- a phenotypic assay according to the invention is conducted on cells obtained from a tumor explant from a patient. Genotypic assays of the invention are performed on genetic data obtained from patient cells, regardless of their source. Thus, a genotypic assay can be performed on somatic cells obtained from the patient or on cells from the same tumor that is evaluated in the phenotypic assay. Assays of the invention can be performed on an individualized basis or on a pool of samples obtained from multiple individual patients. If assays are conducted on pooled samples, the phenotypic characteristics of the pool of samples are determined followed by individualized genotypic assays on specific patients. This allows multiplexing of the phenotypic portion of the assay.
- This invention provides methods for assessing efficacy of chemotherapeutic agents. Specifically, the invention provides methods for assessing the efficacy of chemotherapeutic agents based on phenotypic changes observed in tumor cells obtained from a patient and genetic characteristics of the patient that indicate general or specific chemotherapeutic resistance. In one aspect of the invention, efficacy of a chemotherapeutic agent is assessed based upon the results of the phenotypic and genotypic assays. In another aspect of the invention, chemotherapeutic agents are selected for treating a patient based on the results of the phenotypic and genotypic assays.
- the present invention is also useful for screening of therapeutic agents against other diseases, including but not limited to, hyperproliferative diseases, such as psoriasis.
- agents that retard cell growth are evaluated using methods of the present invention.
- agents that retard cell growth are evaluated using methods of the present invention.
- the effects of therapeutics on the enzymatic processes, neurotransmitters, and biochemical pathways are screened using methods of the invention.
- Methods of the invention can be practiced on any type of cell obtained from a patient, including, but not limited to, normal somatic cells, malignant cells, abnormal proliferating cells, and other diseased cells.
- Cells are obtained from any patient sample, including, but not limited to, blood samples and buccal smears. The skilled artisan recognizes that methods of the invention can be practiced using a variety of different samples.
- a phenotype assay is employed to assess sensitivity and resistance to chemotherapeutic agents.
- the phenotypic assay is performed in vitro using cultured cells.
- the phenotype assay allows for identification and separation of target cells from other cells found in a tissue sample, as well as direct measurement and monitoring of target cells in response to chemotherapeutic treatment.
- Direct measurements and monitoring of live cells are performed using known methods in the art including, for example, the measuring of doubling rate, fraction proliferative assays, monitoring of cytostasis, cell death, cell adhesion, gene expression, angiogenesis, cell motility, and others.
- Direct measurements also include known assays, such as those directed to measurement and monitoring of apoptosis, senescence, and necrosis.
- a genotype assay is performed to determine whether cells from a patient comprise a genetic characteristic associated with resistance to the chemotherapeutic agents.
- Genotype assays reveal latent resistance to chemotherapeutic agents not observed by phenotypic assays.
- Genotypic assays may measure characteristics, such as metabolism, toxic effects, absorption of a therapeutic candidate.
- the phenotypic assay is performed using cell culture monolayers prepared from tumor cells.
- monolayers are cultured from cohesive multicellular particulates generated from a tumor biopsy.
- Explants of tumor tissue sample are prepared non-enzymatically, for initial tissue culture monolayer preparation.
- the multicellular tissue explant is removed from the culture growth medium at a predetermined time to both allow for the growth of target cells and prevent substantial growth of non-target cells such as fibroblasts or stromal cells.
- a cell culture monolayer is prepared in accordance with the invention using the following procedure.
- a biopsy of non-necrotic, non-contaminated tissue is obtained from a patient by any suitable biopsy or surgical procedure known in the art.
- the tissue sample is tumor tissue.
- the size of the biopsy sample is not central to the methods provided herein, but a sample is preferably about 5 to 500 mg, and more preferably about 100 mg.
- Biopsy sample preparation generally proceeds under sterile conditions.
- Cohesive multicellular particulates (explants) are prepared from the tissue sample by enzymatic digestion or mechanical fragmentation. Ideally, mechanical fragmentation of the explant occurs in a medium substantially free of enzymes that are capable of digesting the explant.
- the tissue sample may be minced with sterile scissors to prepare the explants.
- the tissue sample is systematically minced by using two sterile scalpels in a scissor-like motion, or mechanically equivalent manual or automated opposing incisor blades. This cross-cutting motion creates smooth cut edges on the resulting tissue multicellular particulates.
- the particles are plated in culture flasks (for example, 9 explants per T-25 flask or 20 particulates per T-75 flask). The explants are preferably evenly distributed across the bottom surface of the flask, followed by initial inversion for about 10-15 minutes.
- the flask is then be placed in a non-inverted position in a 37°C CO 2 incubator for about 5-10 minutes.
- the tissue sample comprises brain cells
- the flasks are placed in a 35°C, non-CO 2 incubator. Flasks are checked regularly for growth and contamination.
- the multicellular explant is removed from the cell culture at a predetermined time, as described below. Over a period of a few weeks a monolayer is produced. With respect to the culturing of tumor cells, it is believed (without any intention of being bound by the theory) that tumor cells grow out from the multicellular explant prior to contaminating stromal cells. Therefore, by initially maintaining the tissue cells within the explant and removing the explant at a predetermined time, growth of the tumor cells (as opposed to stromal cells) into a monolayer is facilitated. The use of the above procedure to form a cell culture monolayer maximizes the growth of tumor cells from the tissue sample, and thus optimizes the phenotypic and genotypic assays.
- monitoring of the growth of cells may be conducted by visual monitoring of the flasks on a periodic basis, without killing or staining the cells and without removing any cells from the culture flask. Data from periodic counting or measuring is then used to determine growth rates or cell motility, respectively.
- Phenotypic assays are performed on cultured cells using a chemotherapeutic drug response assay with clinically relevant dose concentrations and exposure times.
- One embodiment of the present invention contemplates a phenotypic assay that assesses whether chemotherapeutic agents effect cell growth.
- Monolayer growth rate is monitored using, for example, a phase-contrast inverted microscope.
- culture flasks are incubated in a (5% CO2) incubator at about 37° C. The flask is placed under the phase-contrast inverted microscope, and ten fields (areas on a grid inherent to the flask) are examined using a 10X objective.
- the ten fields should be non-contiguous, or significantly removed from one another, so that the ten fields are a representative sampling of the whole flask. Percentage cell occupancy for each field examined is noted, and averaging of these percentages then provides an estimate of overall percent confluency in the cell culture. When patient samples have been divided between two more flasks, an average cell count for the total patient sample should be calculated. The calculated average percent confluency should be entered into a process log to enable compilation of data--and plotting of growth curves--over time. Alternatively, confluency is judged independently for each flask. Monolayer cultures may be photographed to document cell morphology and culture growth patterns.
- the tissue explant is removed from the growth medium at a predetermined time.
- the explant is removed from the growth medium prior to the emergence of a substantial number of stromal cells from the explant.
- the explant may be removed according to the percent confluency of the cell culture.
- the explant is removed at about 10 to about 50 percent confluency.
- the explant is removed at about 15 to about 25 percent confluency.
- the explant is removed at about 20 percent confluency.
- this method of culturing a multicellular tissue explant and subsequently removing the explant at a predetermined time allows for increased efficiency in both the preparation of cell cultures and subsequent phenotypic and genotypic assays for assessing efficacy of chemotherapeutic agents.
- a phenotypic assay assesses whether chemotherapeutic agents effect cell motility.
- Methods for measuring cell motility are known by persons skilled in the art. Generally, these methods monitor and record the changes in cell position over time. Examples of such methods include, but are not limited to, video microscopy, optical motility scanning (for example, see U.S. Pat. No. 6,238,874 ) and impedance assays.
- cell motility assays are carried out using monolayer cultures of malignant cells as described herein.
- Cell culture methods of the invention permit the expansion of a population of proliferating cells in a mixed population of abnormal proliferating cells and other (normal) cells.
- the mixed population of cells typically is a biopsy or sample from a solid tumor.
- a tissue sample from the patient is harvested, cultured and analyzed for genetic indicia of resistance to chemotherapeutics.
- Subcultures of the cells produced by the culture methods described above may be separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment for the patient.
- procedures for culturing the malignant cells and determining a phenotypic to a chemotherapeutic agent may be performed in the following manner.
- a specimen is finely minced and tumor fragments are plated into tissue culture.
- the cells are then exposed to growth medium, such as a tumor-type defined media with serum.
- the cells are trypsinized, preferably, but not necessarily, when greater than 150,000 cells grown out from tumor fragment.
- the cells are preferably plated into a Terasaki plate at 350 cells per well.
- the cells are analyzed to verify that a majority of cells are tumor epithelial cells.
- Non-adherent cells are removed from the wells.
- the cells are treated with 6 concentrations and 2 control lanes of chemotherapeutic agent or agents for preferably 2 to 4 hours.
- the chemotheraputic agents are removed by washing.
- the cells are incubated for preferably 3 days.
- the living cells are counted to calculate the kill dose that reduces by 40% the number of cells per well from control wells.
- the culture techniques of the present invention result in a monolayer of cells that express cellular markers, secreted factors and tumor antigens in a manner representative of their expression in vivo.
- Specific method innovations such as tissue sample preparation techniques render this method practically, as well as theoretically, useful.
- cells from a patient are analyzed for genetic characteristics (abnormalities) specific to a patient.
- Genetic characteristic of a cell or cell population can be analyzed alone or in combination with other characteristics.
- Genetic characteristics of the invention can be, without limitation, a genetic polymorphism or a mutation, such as an insertion, inversion, deletion, or substitution.
- nucleic acids are isolated from cells of a patient and analyzed to identify genotypic characteristics of the cells.
- the isolated nucleic acid is DNA or RNA.
- the nucleic acid preferably, is analyzed in a microarray for DNA-encoded polymorphisms in the coding or control regions of the gene.
- the nucleic acid is analyzed in a microarray for aberrant expression of one or more genes.
- the microarray contains nucleic acids that are characteristic of known malignancies, as well as nucleic acids, that are not correlated with known malignancies so that previously unknown relationships between gene expression and a proliferative disease or condition may be identified.
- a preferred method of the invention comprises comparing the genotype, or portion thereof, of cells from a patient with genotypes known to be associated with drug resistance generally, or specifically with respect to a therapeutic candidate being evaluated. For example, the existence in patient cells of a polymorphic variant that is known or suspected to confer resistance to a therapeutic candidate would screen that candidate out as a potential therapeutic against those cells.
- EGFR epidermal growth factor receptor
- Rb retinoblastoma
- TGF ⁇ transforming Growth Factor ⁇
- mRNA polyA + mRNA
- labeled cDNA is prepared therefrom.
- the labeled cDNA is prepared by synthesizing a first strand cDNA using an oligo-dT primer, reverse transcriptase and labeled deoxynucleotides, such as, Cy5-dUTP, commercially available from Amersham Pharmacia Biotech. Radio-labeled nucleotides also can be used to prepare cDNA probes.
- the labeled cDNA is hybridized to the microarray under sufficiently stringent conditions to ensure specificity of hybridization of the labeled cDNA to the array DNA.
- the labeled array is visualized. Visualization of the array may be conducted in a variety of ways. For instance, when the reading of the microarray is automated and the labeled DNA is labeled with a fluorescent nucleotide, the intensity of fluorescence for each discreet DNA of the microarray can be measured automatically by a robotic device that includes a light source capable of inducing fluorescence of the labeled cDNA and a spectrophotometer for reading the intensity of the fluorescence for each discreet location in the microarray. The intensity of the fluorescence for each DNA sample in the microarray typically is directly proportional to the quantity of the corresponding species of mRNA in the cells from which the mRNA is isolated.
- cDNA from two cell types (i.e., normal and diseased proliferating cells) and hybridize equivalent amounts of both probe populations to a single microarray to identify differences in RNA expression for both normal and diseased proliferating cells.
- Tools for automating preparation and analysis of microarray assays such as robotic microarrayers and readers, are available commercially from companies such as Gene Logic and Nanogen and are under development by the NHGRI.
- the automation of the microarray analytical process is desirable and, for all practical purposes necessary, due to the huge number and small size of discreet sites on the microarray that must be analyzed.
- DNA microarrays are used in combination with the cell culturing method of the present invention due to the increased sensitivity of mRNA quantification protocols when a substantially pure population of cells are used. For their ease of use and their ability to generate large amounts of data, microarrays are preferred, when practicable. However, certain other or additional qualitative assays may be preferred in order to identify certain markers.
- RNA or DNA species are identified by PCR procedures.
- Known genetic polymorphisms, translocations, or insertions i.e., retroviral insertions or the insertion of mobile elements, such as transposons
- the genetic polymorphisms may be identified by conducting a PCR reaction using a cDNA template.
- Aberrant splicing of RNA precursors also may be identified by conducting a PCR reaction using a cDNA template.
- An expressed translocated sequence may be identified in a microarray assay, such as the Affymetrix p53 assay.
- small or single nucleotide substitutions are identified by the direct sequencing of a given gene by the use of gene-specific oligonucleotides as sequencing primers.
- single nucleotide mutations are identified through the use of allelic discrimination molecular beacon probes, such as those described in Tyagi, S. and Kromer, F.R. (1996) Nature Biotech. 14:303-308 and in Tyagi, S. et al., (1998) Nature Biotech. 16:49-53 .
- Genotypic analysis may be based on experimentation or experience. Sources for such empirical data made be obtained from, but not limited to clinical records and/or animal tumor transplant studies. Genetic characteristics found in the patient cells can be compared to a database containing known tumor genotypes and their respective resistance to chemotherapeutic agents. In a preferred embodiment, a database containing genotypes and their respective drug resistance profile is used to compare genotypic characteristics of the target cells to resistance to chemotherapeutic agents in vivo. Computer algorithms are useful for carrying out pattern matching routines in complex systems, such as genetic data-mining. A linear regression algorithm, for example, can be utilized to analyze a database and identify the genotype most closely matching the genetic characteristics in the patient cells. In one embodiment, a comparative analysis of genotypes is performed using a known linear regression algorithm.
- genotypic characteristics of patient cells are analyzed to establish whether such characteristics are associated with resistance to chemotherapeutic agents in vivo. While the above-mentioned genotypic assays are useful in the analysis of nucleic acids derived from cells produced by the culture methods embodied in the present invention, numerous additional methods are known in the general fields of molecular biology and molecular diagnostics that may be used in place of the above-referenced methods. Information obtained from genotypic assays is analyzed to determine efficacy of chemotherapeutic agents.
- data obtained by practicing the methods of the invention is stored in databases.
- the contents of these databases include, but are not limited to, observed in vitro phenotypes (disease factors) and genotypes (host factors).
- a course of chemotherapy is selected based on results obtained from the phenotypic and genotypic assays.
- the present invention allows for the assessment of the likelihood of whether chemotherapeutic agents will be effective in treating a malignancy in a patient.
- a phenotypic assay in combination with a genotypic assay operates to minimize the risk of administering to a patient a chemotherapeutic agent or combinations of chemotherapeutic agents to which the tumor is resistant.
- chemotherapeutic agents or combinations of chemotherapeutic agents are selected for treatment where an effect on cellular phenotype is observed and the genotypic characteristics associated with resistance are not observed.
- Chemotherapeutic agents that effect cellular phenotype are potential candidates for use in the patient. Known procedures that screen for chemotherapeutic agents are time-consuming and expensive.
- chemotherapeutic agents that effect cellular phenotype and lack genetic changes associated with drug resistance are administered to the patient.
- genotypic characteristics observed in the genetic assay undergo a comparative analysis to determine if such characteristics are associated with drug resistance.
- the phenotypic and genotypic assays are performed in succession, thereby narrowing the scope of the genotypic comparative analysis, and reducing labor costs and associated expenses.
- a patient is treated with the chemotherapeutic agent.
- a patient was diagnosed with breast cancer and chemotherapeutic treatment was prescribed by the treating physician.
- a tumor biopsy of approximately 100 mg of non-necrotic, non-contaminated tissue was harvested from the patient by surgical biopsy and transferred to a laboratory in a standard shipping container. Biopsy sample preparation proceeded as follows. Reagent grade ethanol was used to wipe down the surface of a Laminar flow hood. The tumor was then removed, under sterile conditions, from its shipping container, and cut into quarters with a sterile scalpel.
- each undivided tissue quarter was then placed in 3 ml sterile growth medium (Standard F-10 medium containing 17% calf serum and a standard amount of Penicillin and Streptomycin) and minced by using two sterile scalpels in a scissor-like motion. After each tumor quarter was minced, the particles were plated in culture flasks using sterile pasteur pipettes (9 explants per T-25 or 20 particulates per T-75 flask). Each flask was then labeled with the patient's code and the date of explantation.
- sterile growth medium Standard F-10 medium containing 17% calf serum and a standard amount of Penicillin and Streptomycin
- the explants were evenly distributed across the bottom surface of the flask, with initial inverted incubation in a 37° C incubator for 5-10 minutes, followed by addition of about 5-10 ml sterile growth medium and further incubation in the normal, non-inverted position. Flasks were placed in a 35° C, non-CO 2 incubator. Flasks were checked daily for growth and contamination as the explants grew out into a cell monolayer.
- paclitaxel sold under the trademark TAXOL (Bristol-Myers Squibb Company) was applied to the wells in the microtiter plates.
- Three treatment rows in the plates (Rows 2, 3, and 4) were designed to have escalating paclitaxel doses (1.0, 5.0, and 25 ⁇ M). Row 5 served as a control.
- the paclitaxel exposure time was two hours.
- the cells were allowed to incubate for another 72 hours so that inhibition of cell proliferation can be observed. During this period, the growth inhibiting effect of paclitaxel was monitored by observing the percent of confluency of the cells. For each microtiter well, the percent of confluency of cultured cells was plotted as a function of time.
- DNA was isolated from cells of the patient and analyzed for single nucleotide genetic polymorphisms.
- Known genetic polymorphisms were identified in the DNA by conducting PCR reactions and sequencing a region of interest in the DNA. The DNA region of interest from the patient cells was compared to corresponding regions from known genetic banks and libraries (for example, GENBANK).
- paclitaxel was an efficacious course of treatment for the patient. As a result, paclitaxel was administered to the patient.
- a patient was diagnosed with lung cancer and chemotherapeutic treatment was prescribed by the treating physician.
- a tumor biopsy of approximately 100 mg of non-necrotic, non-contaminated tissue was harvested from the patient by surgical biopsy and transferred to a laboratory in a standard shipping container. The biopsy sample was prepared as described in Example 1.
- the chemotherapeutic agent carboplatin sold under the trademark PARAPLATIN Bristol-Myers Squibb Company
- the first three treatment rows in the plates (Rows 2, 3, and 4) were designed to have escalating carboplatin doses (50, 200, and 1000 ⁇ M). Row 5 serves as a control.
- the carboplatin exposure time was two hours. The cells were allowed to incubate for another 72 hours so that inhibition of cell motility can be observed.
- Cell motility was measured by calculating the distance a cell travels over time.
- Cells were monitored using a digital video-camera mounted on a phase-contrast light microscope. To maintain the growth medium at 35° C, the microscope was fitted with a heated slide stage. After the cultured cells were incubated with carboplatin, cell migration was recorded under 20X magnification. During this period, the motility inhibiting effect of carboplatin was documented by plotting the distance cells travel as a function of time. The distance cells travel was a determined using digital imaging techniques known in the art.
- the cells were subjected to genotypic analysis by comparing DNA from the cultured cells to known genetic banks and libraries.
- Known genetic polymorphisms were identified in the cultured cells by conducting PCR reactions and sequencing a region of interest in DNA isolated from the cultured cells. The DNA region of interest from the cultured cells was compared to corresponding regions from known genetic banks and libraries (for example, GENBANK).
- genotypic assay Genetic characteristcs observed in the genotypic assay were compared to a database of genetic characteristics that were known to be associated with resistance to carboplatin. The phenotypic and genotypic assays were used in combination to determine that carboplatin was an efficacious course of treatment for the patient. As a result, carboplatin was administered to the patient.
Abstract
Description
- This application claims priority to
U.S. Application Serial No. 60/417,439, filed October 12, 2002 U.S. Application Serial No. 10/336,659, filed January 2, 2003 - The invention relates to methods for assessing efficacy of chemotherapeutic agents.
- Cancer chemotherapy involves the use of cytotoxic drugs to destroy unwanted cells in patients. Treatment may consist of using one or more cytotoxic drugs, depending on the nature of the disease being treated. However, drug toxicity and drug resistance are significant barriers effective chemotherapy.
- Toxicity from chemotherapeutic agents produces side effects ranging from mild trauma to death. Moreover, repeated exposure to chemotherapeutic drugs is itself often fatal. As chemotherapeutic drugs are carried in the blood, they are taken up by proliferating cells, including normal cells. Tissues with high growth rates such as bone marrow and epithelial tissues, including the gastrointestinal tract, are normally most susceptible to toxic side effects. Some drugs have additional toxic effects on other tissues, such as the urinary tract, myocardium, or pancreas. Chemotherapeutic agents may cause direct injury to the heart, either acutely, in the form of myocardial tissue injury or dysrhythmias, or in a delayed or chronic fashion associated with congestive heart failure.
- Target cells, such as malignant or diseased cells, may be intrinsically resistant to chemotherapeutic drugs or they may acquire resistance as a result of exposure. A target cell may be genetically predisposed to resistance to particular chemotherapeutics. Alternatively, the cell may not have receptors or activating enzymes for the drug or may not be reliant on the biochemical process with which the drug interferes.
- Acquired resistance also may develop after cells have been exposed to a drug or to similar classes of drugs. One example of acquired drug resistance is the multiple drug resistance phenotype. Multiple drug resistance is a phenomenon of cross-resistance of cells to a variety of chemotherapeutic agents which are not structurally or functionally related. This phenomenon is typically mediated by p-glycoprotein, a cell membrane pump that is present normally on the surface of some epithelial cells. The protein actively removes drug from the cell, making it resistant to drugs that are substrates for the cell membrane pump.
WO9802038 - A critical issue in cancer chemotherapy is the ability to select drugs that not only affect cancer cell phenotype in cell culture assays, but are also not subject to resistance. The present invention addresses that issue.
- The invention provides methods for accurately predicting efficacy of chemotherapeutic agents. Methods of the invention increase the positive predictive value of chemosensitivity assays by assessing both the ability of a chemotherapeutic to affect tumor cells phenotype and the genetic propensity of the patient for resistance to the chemotherapeutic. Results obtained using methods of the invention provide insight into the in vivo effectiveness of a therapeutic, and lead to more effective, individualized, chemotherapeutic choices.
- According to the invention, a phenotype assay screens a therapeutic candidate for the ability to affect the phenotype of tumor cells in culture. A therapeutic candidate that produces the desired phenotypic effect (e.g., cell death, decreased motility, changes in cellular adhesion, angiogenesis, or gene expression, among others) then is screened against genetic properties of cells of the patient which make resistance to the therapeutic candidate likely or possible. A therapeutic candidate that has a desired phenotypic effect on patient tumor cells and that does not appear to be subject to genetic-based resistance is selected for use. As a result of combining phenotypic and genetic data, use of the invention increases the likelihood that a therapeutic candidate, chosen on the basis of its ability to affect cellular phenotype, will be effective when administered to patients.
- Accordingly, the invention provides methods for assessing efficacy of chemotherapeutic agents comprising exposing cells to a chemotherapeutic agent, conducting an assay to determine whether the chemotherapeutic agent affects tumor cell phenotype, and identifying genetic characteristics of cells of the patient (which may or may not be tumor cells) that indicate a propensity for resistance to the chemotherapeutic agent.
- In an embodiment, a phenotypic assay for use in the invention comprises obtaining a tumor explant from a patient, culturing portions of he explant, allowing a multicellular tumor tissue explant to form a cell culture monolayer, removing the explant from the culture prior to the emergence of a substantial number of stromal cells from the explant and growing the monolayer to thereby prevent substantial growth of stromal cells, exposing the monolayer to a drug candidate, and assessing the ability of the drug candidate to alter tumor cell phenotype. A preferred phenotypic assay is disclosed in
U.S. Patent No. 5,728,541 , and in co-owned, co-pendingU.S. Application Serial No. 10/208,480 . - Genotype analysis according to the invention is accomplished by any known method. A preferred method comprises comparing the genotype, or portion thereof, of cells obtained from the patient with genotypes known to be associated with drug resistance generally, or specifically with respect to a therapeutic candidate being evaluated. For example, the existence in patient cells of a polymorphic variant that is known or suspected to confer resistance to a therapeutic candidate would screen that candidate out as a potential therapeutic against those cells. Genetic characteristics of patient cells are determined by methods known in the art (e.g., sequencing, polymorphisms) as set forth below. The impact of a patient's genotype upon drug resistance may be determined by reference to genetic databases or libraries that catalog known mutations or polymorphisms related to resistance.
- The present invention also provides methods for selecting a chemotherapeutic agent for treating a patient based on results obtained from the phenotypic and genotypic assays. In a preferred embodiment, the present invention allows for the assessment of whether a chemotherapeutic agent will be effective in treating a cancer when administered to a patient. According to the invention, chemotherapeutic agents or combinations of chemotherapeutic agents are selected for treatment where an effect on cellular phenotype is observed and characteristics of genetic-based resistance are not observed.
- Methods of the invention are useful in drug or chemotherapeutic agent screening to provide information indicative of the in vivo reactivity of the cells, and thus the specific efficacy as to a particular patient. Methods of the invention are also useful to screen new drug candidates for therapeutic efficacy and to provide a basis for categorizing drugs with respect to the tumor types against which they will work best.
- A phenotypic assay according to the invention is conducted on cells obtained from a tumor explant from a patient. Genotypic assays of the invention are performed on genetic data obtained from patient cells, regardless of their source. Thus, a genotypic assay can be performed on somatic cells obtained from the patient or on cells from the same tumor that is evaluated in the phenotypic assay. Assays of the invention can be performed on an individualized basis or on a pool of samples obtained from multiple individual patients. If assays are conducted on pooled samples, the phenotypic characteristics of the pool of samples are determined followed by individualized genotypic assays on specific patients. This allows multiplexing of the phenotypic portion of the assay.
- This invention provides methods for assessing efficacy of chemotherapeutic agents. Specifically, the invention provides methods for assessing the efficacy of chemotherapeutic agents based on phenotypic changes observed in tumor cells obtained from a patient and genetic characteristics of the patient that indicate general or specific chemotherapeutic resistance. In one aspect of the invention, efficacy of a chemotherapeutic agent is assessed based upon the results of the phenotypic and genotypic assays. In another aspect of the invention, chemotherapeutic agents are selected for treating a patient based on the results of the phenotypic and genotypic assays.
- The present invention is also useful for screening of therapeutic agents against other diseases, including but not limited to, hyperproliferative diseases, such as psoriasis. In addition, the screening of agents that retard cell growth (anti-cancer, anti-hyperproliferative), including agents that enhance or subdue intracellular biochemical functions, are evaluated using methods of the present invention. For example, the effects of therapeutics on the enzymatic processes, neurotransmitters, and biochemical pathways are screened using methods of the invention. Methods of the invention can be practiced on any type of cell obtained from a patient, including, but not limited to, normal somatic cells, malignant cells, abnormal proliferating cells, and other diseased cells. Cells are obtained from any patient sample, including, but not limited to, blood samples and buccal smears. The skilled artisan recognizes that methods of the invention can be practiced using a variety of different samples.
- In one step of the invention, a phenotype assay is employed to assess sensitivity and resistance to chemotherapeutic agents. The phenotypic assay is performed in vitro using cultured cells. The phenotype assay allows for identification and separation of target cells from other cells found in a tissue sample, as well as direct measurement and monitoring of target cells in response to chemotherapeutic treatment. Direct measurements and monitoring of live cells are performed using known methods in the art including, for example, the measuring of doubling rate, fraction proliferative assays, monitoring of cytostasis, cell death, cell adhesion, gene expression, angiogenesis, cell motility, and others. Direct measurements also include known assays, such as those directed to measurement and monitoring of apoptosis, senescence, and necrosis.
- In another step of the invention, a genotype assay is performed to determine whether cells from a patient comprise a genetic characteristic associated with resistance to the chemotherapeutic agents. Genotype assays reveal latent resistance to chemotherapeutic agents not observed by phenotypic assays. Genotypic assays may measure characteristics, such as metabolism, toxic effects, absorption of a therapeutic candidate.
- In one embodiment of the invention, the phenotypic assay is performed using cell culture monolayers prepared from tumor cells. In a preferred embodiment, monolayers are cultured from cohesive multicellular particulates generated from a tumor biopsy. Explants of tumor tissue sample are prepared non-enzymatically, for initial tissue culture monolayer preparation. The multicellular tissue explant is removed from the culture growth medium at a predetermined time to both allow for the growth of target cells and prevent substantial growth of non-target cells such as fibroblasts or stromal cells.
- By way of example, in one embodiment of the invention, a cell culture monolayer is prepared in accordance with the invention using the following procedure. A biopsy of non-necrotic, non-contaminated tissue is obtained from a patient by any suitable biopsy or surgical procedure known in the art. In a preferred embodiment, the tissue sample is tumor tissue. The size of the biopsy sample is not central to the methods provided herein, but a sample is preferably about 5 to 500 mg, and more preferably about 100 mg. Biopsy sample preparation generally proceeds under sterile conditions. Cohesive multicellular particulates (explants) are prepared from the tissue sample by enzymatic digestion or mechanical fragmentation. Ideally, mechanical fragmentation of the explant occurs in a medium substantially free of enzymes that are capable of digesting the explant. For example, the tissue sample may be minced with sterile scissors to prepare the explants. In a particularly preferred embodiment, the tissue sample is systematically minced by using two sterile scalpels in a scissor-like motion, or mechanically equivalent manual or automated opposing incisor blades. This cross-cutting motion creates smooth cut edges on the resulting tissue multicellular particulates. After the tissue sample has been minced, the particles are plated in culture flasks (for example, 9 explants per T-25 flask or 20 particulates per T-75 flask). The explants are preferably evenly distributed across the bottom surface of the flask, followed by initial inversion for about 10-15 minutes. The flask is then be placed in a non-inverted position in a 37°C CO2 incubator for about 5-10 minutes. In another embodiment in which the tissue sample comprises brain cells, the flasks are placed in a 35°C, non-CO2 incubator. Flasks are checked regularly for growth and contamination.
- The multicellular explant is removed from the cell culture at a predetermined time, as described below. Over a period of a few weeks a monolayer is produced. With respect to the culturing of tumor cells, it is believed (without any intention of being bound by the theory) that tumor cells grow out from the multicellular explant prior to contaminating stromal cells. Therefore, by initially maintaining the tissue cells within the explant and removing the explant at a predetermined time, growth of the tumor cells (as opposed to stromal cells) into a monolayer is facilitated. The use of the above procedure to form a cell culture monolayer maximizes the growth of tumor cells from the tissue sample, and thus optimizes the phenotypic and genotypic assays.
- Once a primary culture and its derived secondary monolayer tissue culture has been initiated, the growth of the cells is monitored to oversee growth of the monolayer and ascertain the time to initiate the phenotypic assay. Prior to the phenotypic assay, monitoring of the growth of cells may be conducted by visual monitoring of the flasks on a periodic basis, without killing or staining the cells and without removing any cells from the culture flask. Data from periodic counting or measuring is then used to determine growth rates or cell motility, respectively.
- Phenotypic assays are performed on cultured cells using a chemotherapeutic drug response assay with clinically relevant dose concentrations and exposure times. One embodiment of the present invention contemplates a phenotypic assay that assesses whether chemotherapeutic agents effect cell growth. Monolayer growth rate is monitored using, for example, a phase-contrast inverted microscope. In one embodiment, culture flasks are incubated in a (5% CO2) incubator at about 37° C. The flask is placed under the phase-contrast inverted microscope, and ten fields (areas on a grid inherent to the flask) are examined using a 10X objective. In general, the ten fields should be non-contiguous, or significantly removed from one another, so that the ten fields are a representative sampling of the whole flask. Percentage cell occupancy for each field examined is noted, and averaging of these percentages then provides an estimate of overall percent confluency in the cell culture. When patient samples have been divided between two more flasks, an average cell count for the total patient sample should be calculated. The calculated average percent confluency should be entered into a process log to enable compilation of data--and plotting of growth curves--over time. Alternatively, confluency is judged independently for each flask. Monolayer cultures may be photographed to document cell morphology and culture growth patterns. The applicable formula is:
As an example, therefore, if the estimate of area occupied by the cells is 30% and the total area of the field is 100%, percent confluency is 30/100, or 30%. - Following initial culturing of the multicellular tissue explant, the tissue explant is removed from the growth medium at a predetermined time. In one embodiment, the explant is removed from the growth medium prior to the emergence of a substantial number of stromal cells from the explant. Alternatively, the explant may be removed according to the percent confluency of the cell culture. In one embodiment of the invention, the explant is removed at about 10 to about 50 percent confluency. In a preferred embodiment of the invention, the explant is removed at about 15 to about 25 percent confluency. In a particularly preferred embodiment, the explant is removed at about 20 percent confluency. By removing the explant in either of the above manners, a cell culture monolayer predominantly composed of target cells (e.g., tumor cells) is produced. In turn, a substantial number of non-target cells, such as fibroblasts or other stromal cells, fail to grow within the culture. Ultimately, this method of culturing a multicellular tissue explant and subsequently removing the explant at a predetermined time allows for increased efficiency in both the preparation of cell cultures and subsequent phenotypic and genotypic assays for assessing efficacy of chemotherapeutic agents.
- In another embodiment, a phenotypic assay assesses whether chemotherapeutic agents effect cell motility. Methods for measuring cell motility are known by persons skilled in the art. Generally, these methods monitor and record the changes in cell position over time. Examples of such methods include, but are not limited to, video microscopy, optical motility scanning (for example, see
U.S. Pat. No. 6,238,874 ) and impedance assays. In a preferred embodiment, cell motility assays are carried out using monolayer cultures of malignant cells as described herein. - Cell culture methods of the invention permit the expansion of a population of proliferating cells in a mixed population of abnormal proliferating cells and other (normal) cells. The mixed population of cells typically is a biopsy or sample from a solid tumor. A tissue sample from the patient is harvested, cultured and analyzed for genetic indicia of resistance to chemotherapeutics. Subcultures of the cells produced by the culture methods described above may be separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment for the patient. By way of example, procedures for culturing the malignant cells and determining a phenotypic to a chemotherapeutic agent may be performed in the following manner. First, a specimen is finely minced and tumor fragments are plated into tissue culture. The cells are then exposed to growth medium, such as a tumor-type defined media with serum. The cells are trypsinized, preferably, but not necessarily, when greater than 150,000 cells grown out from tumor fragment. The cells are preferably plated into a Terasaki plate at 350 cells per well. The cells are analyzed to verify that a majority of cells are tumor epithelial cells. Non-adherent cells are removed from the wells. The cells are treated with 6 concentrations and 2 control lanes of chemotherapeutic agent or agents for preferably 2 to 4 hours. The chemotheraputic agents are removed by washing. The cells are incubated for preferably 3 days. The living cells are counted to calculate the kill dose that reduces by 40% the number of cells per well from control wells.
- The culture techniques of the present invention result in a monolayer of cells that express cellular markers, secreted factors and tumor antigens in a manner representative of their expression in vivo. Specific method innovations such as tissue sample preparation techniques render this method practically, as well as theoretically, useful.
- According to the present invention, cells from a patient are analyzed for genetic characteristics (abnormalities) specific to a patient. Genetic characteristic of a cell or cell population can be analyzed alone or in combination with other characteristics. Genetic characteristics of the invention can be, without limitation, a genetic polymorphism or a mutation, such as an insertion, inversion, deletion, or substitution. In one embodiment, nucleic acids are isolated from cells of a patient and analyzed to identify genotypic characteristics of the cells. The isolated nucleic acid is DNA or RNA. The nucleic acid, preferably, is analyzed in a microarray for DNA-encoded polymorphisms in the coding or control regions of the gene. In another embodiment, the nucleic acid is analyzed in a microarray for aberrant expression of one or more genes. In this embodiment, the microarray contains nucleic acids that are characteristic of known malignancies, as well as nucleic acids, that are not correlated with known malignancies so that previously unknown relationships between gene expression and a proliferative disease or condition may be identified.
- A preferred method of the invention comprises comparing the genotype, or portion thereof, of cells from a patient with genotypes known to be associated with drug resistance generally, or specifically with respect to a therapeutic candidate being evaluated. For example, the existence in patient cells of a polymorphic variant that is known or suspected to confer resistance to a therapeutic candidate would screen that candidate out as a potential therapeutic against those cells.
- Methods for isolating and analyzing nucleic acids derived from the cells are known in the art. The presence of known proliferation markers, such as the aberrant expression of one or more genes, the epidermal growth factor receptor (EGFR) cyclin D1, pl6cyclin-kinase inhibitor, retinoblastoma (Rb), transforming Growth Factor β (TGFβ) receptor/smad, MDM2 or p53 genes, may be determined by, for example, northern blotting or quantitative polymerase chain reaction (PCR) methods (i.e., RT-PCR).
- In one embodiment of the present invention, mRNA (polyA+ mRNA) is isolated and labeled cDNA is prepared therefrom. The labeled cDNA is prepared by synthesizing a first strand cDNA using an oligo-dT primer, reverse transcriptase and labeled deoxynucleotides, such as, Cy5-dUTP, commercially available from Amersham Pharmacia Biotech. Radio-labeled nucleotides also can be used to prepare cDNA probes. The labeled cDNA is hybridized to the microarray under sufficiently stringent conditions to ensure specificity of hybridization of the labeled cDNA to the array DNA.
- In another embodiment of the invention, the labeled array is visualized. Visualization of the array may be conducted in a variety of ways. For instance, when the reading of the microarray is automated and the labeled DNA is labeled with a fluorescent nucleotide, the intensity of fluorescence for each discreet DNA of the microarray can be measured automatically by a robotic device that includes a light source capable of inducing fluorescence of the labeled cDNA and a spectrophotometer for reading the intensity of the fluorescence for each discreet location in the microarray. The intensity of the fluorescence for each DNA sample in the microarray typically is directly proportional to the quantity of the corresponding species of mRNA in the cells from which the mRNA is isolated. It is possible to label cDNA from two cell types (i.e., normal and diseased proliferating cells) and hybridize equivalent amounts of both probe populations to a single microarray to identify differences in RNA expression for both normal and diseased proliferating cells. Tools for automating preparation and analysis of microarray assays, such as robotic microarrayers and readers, are available commercially from companies such as Gene Logic and Nanogen and are under development by the NHGRI. The automation of the microarray analytical process is desirable and, for all practical purposes necessary, due to the huge number and small size of discreet sites on the microarray that must be analyzed.
- In a further embodiment, DNA microarrays are used in combination with the cell culturing method of the present invention due to the increased sensitivity of mRNA quantification protocols when a substantially pure population of cells are used. For their ease of use and their ability to generate large amounts of data, microarrays are preferred, when practicable. However, certain other or additional qualitative assays may be preferred in order to identify certain markers.
- In another embodiment, the presence of, or absence of, specific RNA or DNA species are identified by PCR procedures. Known genetic polymorphisms, translocations, or insertions (i.e., retroviral insertions or the insertion of mobile elements, such as transposons) often can be identified by conducting PCR reactions with DNA isolated from cells cultured by the methods of the present invention. Where the sequence anomalies are located in exons, the genetic polymorphisms may be identified by conducting a PCR reaction using a cDNA template. Aberrant splicing of RNA precursors also may be identified by conducting a PCR reaction using a cDNA template. An expressed translocated sequence may be identified in a microarray assay, such as the Affymetrix p53 assay.
- In one embodiment, small or single nucleotide substitutions are identified by the direct sequencing of a given gene by the use of gene-specific oligonucleotides as sequencing primers. In a further embodiment, single nucleotide mutations are identified through the use of allelic discrimination molecular beacon probes, such as those described in Tyagi, S. and Kromer, F.R. (1996) Nature Biotech. 14:303-308 and in Tyagi, S. et al., (1998) Nature Biotech. 16:49-53.
- Genotypic analysis may be based on experimentation or experience. Sources for such empirical data made be obtained from, but not limited to clinical records and/or animal tumor transplant studies. Genetic characteristics found in the patient cells can be compared to a database containing known tumor genotypes and their respective resistance to chemotherapeutic agents. In a preferred embodiment, a database containing genotypes and their respective drug resistance profile is used to compare genotypic characteristics of the target cells to resistance to chemotherapeutic agents in vivo. Computer algorithms are useful for carrying out pattern matching routines in complex systems, such as genetic data-mining. A linear regression algorithm, for example, can be utilized to analyze a database and identify the genotype most closely matching the genetic characteristics in the patient cells. In one embodiment, a comparative analysis of genotypes is performed using a known linear regression algorithm.
- According to the invention, genotypic characteristics of patient cells are analyzed to establish whether such characteristics are associated with resistance to chemotherapeutic agents in vivo. While the above-mentioned genotypic assays are useful in the analysis of nucleic acids derived from cells produced by the culture methods embodied in the present invention, numerous additional methods are known in the general fields of molecular biology and molecular diagnostics that may be used in place of the above-referenced methods. Information obtained from genotypic assays is analyzed to determine efficacy of chemotherapeutic agents.
- In a further embodiment of the invention, data obtained by practicing the methods of the invention, including phenotypic, genotypic and patient outcome information, is stored in databases. The contents of these databases include, but are not limited to, observed in vitro phenotypes (disease factors) and genotypes (host factors). By applying analytical techniques to the stored information, predictions of chemotherapeutic efficacy can be made. Methods of the invention allow for the skilled practitioner to accurately select an effective course of chemotherapy for a patients, thus reducing the risk of treatment-related trauma and resistance.
- In one aspect of the invention, a course of chemotherapy is selected based on results obtained from the phenotypic and genotypic assays. The present invention allows for the assessment of the likelihood of whether chemotherapeutic agents will be effective in treating a malignancy in a patient. A phenotypic assay in combination with a genotypic assay operates to minimize the risk of administering to a patient a chemotherapeutic agent or combinations of chemotherapeutic agents to which the tumor is resistant. In one aspect of the invention, chemotherapeutic agents or combinations of chemotherapeutic agents are selected for treatment where an effect on cellular phenotype is observed and the genotypic characteristics associated with resistance are not observed.
- Chemotherapeutic agents that effect cellular phenotype are potential candidates for use in the patient. Known procedures that screen for chemotherapeutic agents are time-consuming and expensive. In one embodiment of the invention, chemotherapeutic agents that effect cellular phenotype and lack genetic changes associated with drug resistance are administered to the patient. In a further embodiment, genotypic characteristics observed in the genetic assay undergo a comparative analysis to determine if such characteristics are associated with drug resistance. In another embodiment, the phenotypic and genotypic assays are performed in succession, thereby narrowing the scope of the genotypic comparative analysis, and reducing labor costs and associated expenses. In one aspect of the invention, when it is determined that a chemotherapeutic agent effects cellular phenotype and is not associated with resistance to cells having the genotypic change, a patient is treated with the chemotherapeutic agent.
- The following examples provide further details of methods according to the invention. For purposes of exemplification, the following examples provide details of the use of methods of the present invention in colorectal cancer detection. Accordingly, while exemplified in the following manner, the invention is not so limited and the skilled artisan will appreciate its wide range of application upon consideration thereof.
- A patient was diagnosed with breast cancer and chemotherapeutic treatment was prescribed by the treating physician. A tumor biopsy of approximately 100 mg of non-necrotic, non-contaminated tissue was harvested from the patient by surgical biopsy and transferred to a laboratory in a standard shipping container. Biopsy sample preparation proceeded as follows. Reagent grade ethanol was used to wipe down the surface of a Laminar flow hood. The tumor was then removed, under sterile conditions, from its shipping container, and cut into quarters with a sterile scalpel. Using sterile forceps, each undivided tissue quarter was then placed in 3 ml sterile growth medium (Standard F-10 medium containing 17% calf serum and a standard amount of Penicillin and Streptomycin) and minced by using two sterile scalpels in a scissor-like motion. After each tumor quarter was minced, the particles were plated in culture flasks using sterile pasteur pipettes (9 explants per T-25 or 20 particulates per T-75 flask). Each flask was then labeled with the patient's code and the date of explantation. The explants were evenly distributed across the bottom surface of the flask, with initial inverted incubation in a 37° C incubator for 5-10 minutes, followed by addition of about 5-10 ml sterile growth medium and further incubation in the normal, non-inverted position. Flasks were placed in a 35° C, non-CO2 incubator. Flasks were checked daily for growth and contamination as the explants grew out into a cell monolayer.
- Following initiation of prime cell culture of the tumor specimen, cells were removed from the monolayers grown in the flasks for centrifugation into standard size cell pellets. Each cell pellet was then suspended in 5 ml of the above-described medium and was mixed in a conical tube with a vortex for 6 to 10 seconds, followed by manual rocking back and forth 10 times. A 36 ml droplet from the center of each tube was then pipetted into one well of a 96-well microtiter plate together with an equal amount of trypan blue, plus stirring. The resulting admixture was then divided between two hemocytometer quadrants for examination using a standard light microscope. Cells were counted in two out of four hemocytometer quadrants, under 10X magnification--only those cells which did not take up the trypan blue dye were counted. This process was repeated for the second counting chamber. An average cell count per chamber was calculated, and the optimum concentration of cells in the medium was determined.
- Accommodating the above calculations, additional cell aliquots from the 4 monolayers were separately suspended in growth medium via vortex and rocking and were loaded into a Terasaki dispenser adapted to a 60-well plate. Aliquots of the prepared cell suspension were delivered into the microtiter plates using Terasaki dispenser techniques. Cells were plated into 60-well microtiter plates at a concentration of 100 cells per well.
- Twenty-four hours post-plating, the chemotherapeutic agent paclitaxel sold under the trademark TAXOL (Bristol-Myers Squibb Company) was applied to the wells in the microtiter plates. Three treatment rows in the plates (Rows 2, 3, and 4) were designed to have escalating paclitaxel doses (1.0, 5.0, and 25 µM). Row 5 served as a control. The paclitaxel exposure time was two hours. The cells were allowed to incubate for another 72 hours so that inhibition of cell proliferation can be observed. During this period, the growth inhibiting effect of paclitaxel was monitored by observing the percent of confluency of the cells. For each microtiter well, the percent of confluency of cultured cells was plotted as a function of time.
- Since paclitaxel affected growth rate of the cultured cells, cells from the patient were subjected to genotypic analysis. DNA was isolated from cells of the patient and analyzed for single nucleotide genetic polymorphisms. Known genetic polymorphisms were identified in the DNA by conducting PCR reactions and sequencing a region of interest in the DNA. The DNA region of interest from the patient cells was compared to corresponding regions from known genetic banks and libraries (for example, GENBANK).
- The phenotypic and genotypic assays were used in combination to determine that paclitaxel was an efficacious course of treatment for the patient. As a result, paclitaxel was administered to the patient.
- A patient was diagnosed with lung cancer and chemotherapeutic treatment was prescribed by the treating physician. A tumor biopsy of approximately 100 mg of non-necrotic, non-contaminated tissue was harvested from the patient by surgical biopsy and transferred to a laboratory in a standard shipping container. The biopsy sample was prepared as described in Example 1. Twenty-four hours post-plating, the chemotherapeutic agent carboplatin sold under the trademark PARAPLATIN (Bristol-Myers Squibb Company) was applied to the wells in the microtiter plates. The first three treatment rows in the plates (Rows 2, 3, and 4) were designed to have escalating carboplatin doses (50, 200, and 1000 µM). Row 5 serves as a control. The carboplatin exposure time was two hours. The cells were allowed to incubate for another 72 hours so that inhibition of cell motility can be observed.
- Cell motility was measured by calculating the distance a cell travels over time. Cells were monitored using a digital video-camera mounted on a phase-contrast light microscope. To maintain the growth medium at 35° C, the microscope was fitted with a heated slide stage. After the cultured cells were incubated with carboplatin, cell migration was recorded under 20X magnification. During this period, the motility inhibiting effect of carboplatin was documented by plotting the distance cells travel as a function of time. The distance cells travel was a determined using digital imaging techniques known in the art.
- Since carboplatin affected cell motility in the tumor cells, the cells were subjected to genotypic analysis by comparing DNA from the cultured cells to known genetic banks and libraries. Known genetic polymorphisms were identified in the cultured cells by conducting PCR reactions and sequencing a region of interest in DNA isolated from the cultured cells. The DNA region of interest from the cultured cells was compared to corresponding regions from known genetic banks and libraries (for example, GENBANK).
- Genetic characteristcs observed in the genotypic assay were compared to a database of genetic characteristics that were known to be associated with resistance to carboplatin. The phenotypic and genotypic assays were used in combination to determine that carboplatin was an efficacious course of treatment for the patient. As a result, carboplatin was administered to the patient.
- While the invention has been shown and described with reference to specific preferred embodiments, it should be understood by those skilled in the art that various changes in form and detail may be made therein within the scope of the invention as defined by the following claims.
Claims (18)
- A method for assessing chemotherapeutic efficacy for a cancer patient, comprising:allowing a multicellular tumor tissue explant of the patient to form a cell culture monolayer,removing the explant from the culture prior to the emergence of a substantial number of stromal cells from the explant and growing the monolayer to thereby prevent substantial growth of stromal cells;optionally preparing a subculture from the monolayer cells;conducting at least one phenotypic assay on cells from the monolayer or the subculture, so as to determine a tumor cell phenotype predictive of a drug's efficacy against the tumor;conducting at least one genotypic analysis of cells from the patient to determine the presence or absence of a genotype predictive of resistance to said drug;thereby assessing whether the drug will be an effective chemotherapy for the patient.
- The method of claim 1, wherein the explant is from a solid tumor.
- The method of claim 1, wherein the explant is prepared by mechanical fragmentation of tumor tissue in a medium substantially free of enzymes that are capable of digesting the explant.
- The method of claim 1, wherein the explant is prepared by systematic mincing of the tumor tissue.
- The method of claim 1, wherein the multicellular tissue explant is removed from the culture when the monolayer is at from 10% to 50% confluency.
- The method of claim 1, wherein the multicellular tissue explant is removed from the culture when the monolayer is at from 15% to 30% confluency.
- The method of claim 1, wherein the at least one phenotypic assay comprises a drug response assay.
- The method of claim 7, wherein the drug is an anti-proliferative agent.
- The method of claim 7, wherein the drug response assay measures one or more of cell death, cell growth; apoptosis, changes in cell motility, changes in cell adhesion, or changes in gene expression upon exposure of the cultured cells to a drug.
- The method of claim 1, wherein the at least one phenotypic assay comprises an assay for expression of a cellular marker, secreted factor, or tumor antigen.
- The method of claim 1, wherein the at least one phenotypic assay comprises an assay for aberrant gene expression of one or more proliferation markers.
- The method of claim 11, wherein the one or more proliferation markers comprise at least one marker selected from epidermal growth factor receptor (EGFR), cyclin D1, p16/ cyclin-dependent kinase inhibitor, retinoblastoma (Rb), Transforming Growth Factor β (TGFβ) receptor, MDM2, and p53.
- The method of claim 1, wherein the genotype is an allelic variant and/or a single nucleotide polymorphism.
- The method of claim 1, wherein the genotypic analysis is conducted on somatic cells from the patient.
- The method of claim 1, wherein the genotypic analysis is conducted on a blood sample or a buccal smear from the patient.
- The method of claim 1, wherein the genotypic analysis is conducted on cells of the monolayer or the subculture.
- The method of claim 1, wherein the genotypic analysis comprises determining a drug resistance profile for the patient.
- The method of claim 1, wherein the genotypic analysis is predictive of one or more of drug metabolism, drug toxicity, and drug absorption.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US336659 | 1999-06-18 | ||
US41743902P | 2002-10-10 | 2002-10-10 | |
US417439P | 2002-10-10 | ||
US10/336,659 US20040072722A1 (en) | 2002-10-10 | 2003-01-02 | Methods for assessing efficacy of chemotherapeutic agents |
PCT/US2003/032285 WO2004035833A1 (en) | 2002-10-10 | 2003-10-10 | Methods for assessing efficacy of chemotherapeutic agents |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1556515A1 EP1556515A1 (en) | 2005-07-27 |
EP1556515A4 EP1556515A4 (en) | 2007-11-07 |
EP1556515B1 true EP1556515B1 (en) | 2009-11-25 |
Family
ID=32072939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03779093A Expired - Lifetime EP1556515B1 (en) | 2002-10-10 | 2003-10-10 | Methods for assessing efficacy of chemotherapeutic agents |
Country Status (6)
Country | Link |
---|---|
US (4) | US20040072722A1 (en) |
EP (1) | EP1556515B1 (en) |
AT (1) | ATE449869T1 (en) |
AU (1) | AU2003285866A1 (en) |
DE (1) | DE60330266D1 (en) |
WO (1) | WO2004035833A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728541A (en) * | 1996-07-12 | 1998-03-17 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays |
US20040023375A1 (en) | 2002-07-30 | 2004-02-05 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays |
US20040072722A1 (en) | 2002-10-10 | 2004-04-15 | Kornblith Paul L. | Methods for assessing efficacy of chemotherapeutic agents |
US7276351B2 (en) | 2003-09-10 | 2007-10-02 | Seahorse Bioscience | Method and device for measuring multiple physiological properties of cells |
US8658349B2 (en) | 2006-07-13 | 2014-02-25 | Seahorse Bioscience | Cell analysis apparatus and method |
US20070087401A1 (en) * | 2003-10-17 | 2007-04-19 | Andy Neilson | Analysis of metabolic activity in cells using extracellular flux rate measurements |
US7042565B2 (en) * | 2004-02-13 | 2006-05-09 | Kaiwood Technology Co., Ltd. | Fluorescent microarray analyzer |
AU2006287175A1 (en) * | 2005-09-01 | 2007-03-08 | Precision Therapeutics, Inc. | Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics |
CA2631236C (en) * | 2005-12-01 | 2019-10-29 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
EP2136630A4 (en) * | 2007-03-23 | 2010-06-02 | Precision Therapeutics Inc | Methods for evaluating angiogenic potential in culture |
EP2207892A4 (en) | 2007-10-15 | 2010-12-08 | Precision Therapeutics Inc | Methods for selecting active agents for cancer treatment |
US20100311084A1 (en) * | 2008-05-14 | 2010-12-09 | Precision Therapeutics, Inc. | Methods for predicting a patient's response to egfr inhibitors |
US8202702B2 (en) * | 2008-10-14 | 2012-06-19 | Seahorse Bioscience | Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision |
US20110238322A1 (en) * | 2008-11-03 | 2011-09-29 | Precision Therapeutics, Inc. | Methods of simulating chemotherapy for a patient |
DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
US20110097748A1 (en) * | 2009-10-28 | 2011-04-28 | Warsaw Orthopedic, Inc. | Use of cell lines to determine levels of efficacy of pharmaceutical formulations |
WO2011135459A2 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
SG10201508662SA (en) | 2011-10-28 | 2015-11-27 | Presage Biosciences Inc | Methods for drug delivery |
US9494577B2 (en) | 2012-11-13 | 2016-11-15 | Seahorse Biosciences | Apparatus and methods for three-dimensional tissue measurements based on controlled media flow |
GB2516196B (en) | 2013-01-25 | 2015-09-09 | Xcell Biosciences Inc | Methods, compositions, kits, and systems for selective enrichment of target cells |
DE102013010528B3 (en) * | 2013-06-25 | 2014-02-20 | FLACOD GmbH | Creating database for preliminary estimation of effectiveness of cytostatic active substance in chemotherapeutic treatment of tumor, by incubating tumor cells of previously removed tumor tissue sample from patients |
EP3148700B1 (en) | 2014-06-02 | 2020-03-18 | Agilent Technologies, Inc. | Single column microplate system and carrier for analysis of biological samples |
FI3198035T3 (en) | 2014-09-26 | 2023-01-31 | Methods for predicting drug responsiveness | |
US9566012B2 (en) | 2014-10-27 | 2017-02-14 | Medtronic, Inc. | Method and apparatus for selection and use of virtual sensing vectors |
US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4423145A (en) * | 1981-05-07 | 1983-12-27 | Stampfer Martha R | Enhanced growth medium and method for culturing human mammary epithelial cells |
US4668618A (en) | 1981-09-14 | 1987-05-26 | Thornthwaite Jerry T | Nuclear isolation medium and procedure for separating cell nuclei |
US4559299A (en) * | 1983-02-04 | 1985-12-17 | Brown University Research Foundation Inc. | Cytotoxicity assays in cell culturing devices |
US4937187A (en) * | 1983-02-04 | 1990-06-26 | Brown University Research Foundation | Methods for separating malignant cells from clinical specimens |
US4816395A (en) * | 1985-12-19 | 1989-03-28 | Peralta Cancer Research Institute | Method for predicting chemosensitivity of anti-cancer drugs |
US5266480A (en) | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
US4996145A (en) * | 1987-10-27 | 1991-02-26 | Oncotech Incorporated | Method for detecting immune-mediated cytotoxicity |
US5242806A (en) * | 1990-05-07 | 1993-09-07 | Baxter Diagnostics Inc. | Method for conducting the cytotoxicity assays on tumor cells |
US5874218A (en) | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
US5270172A (en) * | 1991-04-26 | 1993-12-14 | Dekk-Tek, Inc. | Method to predict tumor response to therapy |
US5407653A (en) * | 1991-06-26 | 1995-04-18 | Brigham And Women's Hospital | Evaluation of the multidrug resistance phenotype |
JPH07503943A (en) * | 1991-10-29 | 1995-04-27 | クローバー コンソリデイテッド,リミテッド | Cross-linked polysaccharides, polycations and lipids useful for encapsulation and drug release |
WO1994000470A1 (en) | 1992-06-30 | 1994-01-06 | The Wistar Institute Of Anatomy And Biology | DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES |
GB9419716D0 (en) | 1994-09-30 | 1994-11-16 | Gearey David | Electrochemical assessment of cell behaviour and metabolic activity |
US5607918A (en) | 1995-03-01 | 1997-03-04 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-B and DNA coding therefor |
US5888765A (en) | 1995-06-23 | 1999-03-30 | President And Fellows Of Harvard College | Endothelial-cell specific promoter |
US6020473A (en) | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
US5942385A (en) * | 1996-03-21 | 1999-08-24 | Sugen, Inc. | Method for molecular diagnosis of tumor angiogenesis and metastasis |
US20020168679A1 (en) * | 1998-06-11 | 2002-11-14 | Gregory J. Naus | Staining agents and protocols for characterizing malignant cells in culture |
US20040023375A1 (en) * | 2002-07-30 | 2004-02-05 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays |
US20040072722A1 (en) | 2002-10-10 | 2004-04-15 | Kornblith Paul L. | Methods for assessing efficacy of chemotherapeutic agents |
US5728541A (en) * | 1996-07-12 | 1998-03-17 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays |
US6416967B2 (en) * | 1996-07-12 | 2002-07-09 | Precision Therapeutics, Inc. | Method of using multicellular particulates to analyze malignant or hyperproliferative tissue |
US6008007A (en) * | 1997-01-31 | 1999-12-28 | Oncotech, Inc. | Radiation resistance assay for predicting treatment response and clinical outcome |
US5840507A (en) * | 1997-03-19 | 1998-11-24 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis |
US5972639A (en) * | 1997-07-24 | 1999-10-26 | Irori | Fluorescence-based assays for measuring cell proliferation |
US6074874A (en) | 1997-08-29 | 2000-06-13 | University Of Pittsburgh | Epithelial cell cultures for in vitro testing |
US6111092A (en) * | 1998-06-03 | 2000-08-29 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding DRT111 and uses thereof |
US6664062B1 (en) * | 1998-07-20 | 2003-12-16 | Nuvelo, Inc. | Thymidylate synthase gene sequence variances having utility in determining the treatment of disease |
WO2000052204A2 (en) * | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
EP1059352A1 (en) | 1999-06-08 | 2000-12-13 | Oncodia AG | Long term cell culture of human carcinoma |
AU1465801A (en) * | 1999-11-03 | 2001-05-14 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis |
EP1228370A2 (en) * | 1999-11-10 | 2002-08-07 | Structural Bioinformatics Inc. | Computationally derived protein structures in pharmacogenomics |
AU2001240998A1 (en) * | 2000-03-06 | 2001-09-17 | Technion Research And Development Foundation Ltd. | Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy |
JP5156163B2 (en) * | 2000-04-18 | 2013-03-06 | ビルコ・ビーブイビーエイ | Drug resistance measurement method |
AU2002224435A1 (en) | 2000-10-18 | 2002-04-29 | Precision Therapeutics, Inc. | Method for tandem genomic/proteomic analyses of proliferating cells |
WO2002057499A2 (en) * | 2001-01-12 | 2002-07-25 | Washington State University Research Foundation | Mdr1 variants and methods for their use |
US20040086888A1 (en) | 2001-10-18 | 2004-05-06 | Kornblith Paul L | Method for tandem genomic/proteomic analysis of proliferating cells |
JP3923366B2 (en) * | 2001-10-24 | 2007-05-30 | 財団法人癌研究会 | Judgment method of cell anticancer drug sensitivity |
WO2003044215A2 (en) * | 2001-11-20 | 2003-05-30 | Oncomedx, Inc. | Methods for evaluating drug-resistance gene expression in the cancer patient |
AU2006287175A1 (en) * | 2005-09-01 | 2007-03-08 | Precision Therapeutics, Inc. | Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics |
-
2003
- 2003-01-02 US US10/336,659 patent/US20040072722A1/en not_active Abandoned
- 2003-10-10 AU AU2003285866A patent/AU2003285866A1/en not_active Abandoned
- 2003-10-10 WO PCT/US2003/032285 patent/WO2004035833A1/en not_active Application Discontinuation
- 2003-10-10 AT AT03779093T patent/ATE449869T1/en not_active IP Right Cessation
- 2003-10-10 EP EP03779093A patent/EP1556515B1/en not_active Expired - Lifetime
- 2003-10-10 DE DE60330266T patent/DE60330266D1/en not_active Expired - Lifetime
-
2007
- 2007-03-05 US US11/713,662 patent/US7575868B2/en not_active Expired - Fee Related
-
2009
- 2009-07-28 US US12/510,671 patent/US7829288B2/en not_active Expired - Fee Related
-
2010
- 2010-10-05 US US12/898,232 patent/US8039213B2/en not_active Expired - Fee Related
Non-Patent Citations (5)
Title |
---|
BRANGI ET AL: "Camptothecin resistance: Role of the ATP binding casette", CANCER RESEARCH, vol. 59, December 1999 (1999-12-01), pages 5938 - 5946 * |
CHANG ET AL: "Novel mutation of Topoisomerase I in rendering cells resistant to Camptothecin", CANCER RESEARCH, vol. 62, 1 July 2002 (2002-07-01), pages 3716 - 3721 * |
KAVALLARIS ET AL: "Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells", CANCER RESEARCH, vol. 61, 1 August 2001 (2001-08-01), pages 5803 - 5809 * |
PLATH ET AL: "Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy induced apoptosis", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 94, no. 2, 16 January 2002 (2002-01-16), pages 129 - 142 * |
SOTIRIOU ET AL: "Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer", BREAST CANCER RESEARCH, vol. 4, no. r3, 20 March 2002 (2002-03-20) * |
Also Published As
Publication number | Publication date |
---|---|
WO2004035833A1 (en) | 2004-04-29 |
EP1556515A4 (en) | 2007-11-07 |
DE60330266D1 (en) | 2010-01-07 |
US20040072722A1 (en) | 2004-04-15 |
AU2003285866A1 (en) | 2004-05-04 |
ATE449869T1 (en) | 2009-12-15 |
EP1556515A1 (en) | 2005-07-27 |
US7575868B2 (en) | 2009-08-18 |
US8039213B2 (en) | 2011-10-18 |
US20110020826A1 (en) | 2011-01-27 |
US20090286255A1 (en) | 2009-11-19 |
US7829288B2 (en) | 2010-11-09 |
US20080032298A1 (en) | 2008-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7829288B2 (en) | Methods for assessing efficacy of chemotherapeutic agents | |
US8236489B2 (en) | Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics | |
JP5237076B2 (en) | Diagnosis and prognosis of breast cancer patients | |
JP5213202B2 (en) | Detection and use of cell arrays and markers of genetic disorders | |
US20080145841A1 (en) | Diagnostic Tool For Diagnosing Benign Versus Malignant Thyroid Lesions | |
US20020081612A1 (en) | Detection and diagnosis of smoking related cancers | |
US20060160114A1 (en) | Reagents and methods for predicting drug resistance | |
US20040086888A1 (en) | Method for tandem genomic/proteomic analysis of proliferating cells | |
US20080280768A1 (en) | Reagents and Methods for Predicting Drug Resistance | |
US20110130302A1 (en) | Biological pathways associated with chemotherapy outcome for breast cancer | |
Zeschnigk et al. | Prognostic testing in uveal melanoma | |
Iqbal | Molecular Hematology in Leukemia Biology and Treatment: Past, Present, and Future | |
WO2002033117A2 (en) | Method for tandem genomic/proteomic analyses of proliferating cells | |
Zhang | Advanced diagnosis technologies for HER2 breast cancer markers | |
Vaidya et al. | A review of bioinformatics application in breast cancer research | |
Tucker | Radiation cytogenetics: from chromosomes to single nucleotides and from metaphase cells to tissues | |
KR20070051033A (en) | Method for diagnosing hyperplastic polyp of intestine | |
Fey | The impact of chip technology on cancer medicine | |
KR100632325B1 (en) | Dna chip for gene expression monitoring about apoptosis | |
KR20200017084A (en) | High-speed detection kit for Human Leukocyte Antigen(HLA) mutation gene | |
Bonassi et al. | Application of biomarkers in human population studies | |
Mørk | Molecular profiling of Ductal Carcinoma In Situ | |
Järvinen et al. | 27 Identification of putative target genes in cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050502 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20071008 |
|
17Q | First examination report despatched |
Effective date: 20080820 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60330266 Country of ref document: DE Date of ref document: 20100107 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20091125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100325 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100225 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100308 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100226 |
|
26N | No opposition filed |
Effective date: 20100826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101031 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101010 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100526 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101010 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091125 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20121107 Year of fee payment: 10 Ref country code: DE Payment date: 20121029 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20121025 Year of fee payment: 10 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20131010 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20131010 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60330266 Country of ref document: DE Effective date: 20140501 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20140630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140501 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20131031 |